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Abstract: The effects of salsolinol on the mucosal mast cells in the rat gut
Mast cells in the gastrointestinal tract have been found in close spatial contact with the regulatory 
cells of gastrointestinal motility: interstitial cells of Cajal (ICC) and myenteric neurons, suggesting 
their functional interaction. Because of the regulatory role of mast cells even the slight damage 
or change in activity of these cells may cause considerable disorder of the gut motility. The 
catechol isoquinoline derivatives are endogenous compounds present in the mammalian brain and 
the representative one is referred to as salsolinol. Increased salsolinol levels are detected in the 
cerebrospinal fluid of Parkinson’s disease patients. Gastrointestinal dysmotility in those patients 
has been associated with peripheral action of salsolinol. The aim of this study was to evaluate 
effects of exogenous salsolinol on mast cells in the gastrointestinal tract of rats. 
 Male Wistar rats (n = 8) were injected intraperitoneally with salsolinol (50 mg/kg/day) for 
3 weeks and the equal group served as a control. On the last day the animals were sacrificed, 
stomachs, small and large intestines were removed, and paraffin embedded specimens were 
prepared. Slides were toluidine blue stained and the total number and percentage of degranulated 
mast cells in gastric antral, duodenal and ascending colon wall were assessed by image 
analysis. 
 The number of mast cells in the gastrointestinal wall was decreased in the salsolinol group 
compared to the control — in the stomach 98.7  ±  53.3 vs. 156.7  ±  45.8, in the duodenum 2.6  ±  2.1 
vs. 7.83  ±  7.8 and in colon 12.8  ±  14 vs.10.7  ±  17.1 (salsolinol treated vs. control group). Carried 
out examinations showed the destructive action of salsolinol on the mast cells in all segments 
examined of gastrointestinal tract.
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INTRODUCTION
The most diverse collection of nerves outside the central nervous system and 
the most extensive immune system in the body are hidden in the gastrointes-
tinal system. Exposure to luminal factors, such as environmental irritants and 
infectious agents, triggers adaptive processes serving to restore homeostasis, 
where both neuroendocrine and immune responses are involved [1]. The neural 
apparatus of the gut is composed of a large number of enteric neurones ar-
ranged in networks of enteric ganglia, located mainly in the submucosal and 
myenteric plexus, and connected by interganglionic strands [2]. The enteric 
nervous system (ENS) stores a library of programs that generate specific pat-
terns of stereotyped motor behaviour. The enteric immune system cooperates 
with the ENS to establish a first line defence. Several cell types, including 
lymphocytes, macrophages, dendrocytes and mast cells can be found in close 
anatomic association with enteric neurons, vagal nerves fibres and spinal sen-
sory nerves. However, the most is known about enteric mast cells and enteric 
neurons interplay [3].
Communication between the central nervous system (CNS) and mast cells 
in the gut mucosa may occur through various pathways, of which the most 
important occurs at a local level, through intrinsic reflexes. Both mast cells 
and sensory neurons code information by releasing chemical message that is 
decoded by processing circuits in the nervous system. At the same time, en-
teric mast cells are used by the central nervous system as a link for sending 
chemical signals to the ENS [3, 4]. Reports of Pavlovian conditioning of enteric 
mast cell degranulation gives direct evidence for a brain-mast cell connection 
[5]. Therefore, mast cells participate in the modulation of a wide variety of gas-
trointestinal (GI) physiological and pathological processes.
Epidemiological evidence has revealed that gastrointestinal dysfunctions 
may constitute the initial clinical feature of Parkinson’s disease (PD) and oc-
cur long before typical PD symptoms [6]. Neuroactive substances, which may 
induce the disease, are suggested to enter the body via the gastrointestinal 
tract, and attack the nervous system via enteric plexuses and preganglionic 
vagal fibres [7]. Catechol isoquinoline derivatives are endogenous compounds 
proposed as candidates of dopaminergic neurotoxins. The representative one 
is referred to as salsolinol (1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquino-
line), which can be endogenously synthesized from dopamine and acetaldehyde 
by salsolinol synthase or, alternatively, from dopamine and pyruvic acid [8]. 
Properties of salsolinol, as a neurotoxin eliciting symptoms almost identical to 
idiopathic Parkinson’s disease, are intensively studied [9].
The aim of this study was to evaluate the influence of exogenous salsolinol 
on mucosal mast cells in the gastrointestinal tract of Wistar rats. 
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MATERIALS AND METHODS
Sixteen male Wistar rats (Poland) weighting 200  ±  20g were used for the 
study. The animals were housed individually in cages at constant temperature 
22–24°C and on a 12 : 12 hour light: dark schedule. Solid chow and tap water 
were accessible ad libitum. The rats were randomly divided into 2 equal groups. 
One group (n = 8) was subjected to intraperitoneal injections with salsolinol 
(50 mg/kg/day; Sigma, USA) for 21 days and the other group (n = 8) served 
as the control. The experimental protocol was approved by the Jagiellonian 
University Bioethical Committee. 
On the last day of the experiment animals were sacrificed, and stomachs, 
small and large intestines were removed. All tissue fragments were formalin 
fixed and paraffin-embedded 5 µm slices were prepared. Specimens were tolui-
dine blue stained for mast cells assessment. 
Images were collected using light microscope Axiophot (Zeiss) equipped with 
colour camcorder ProgRes C12 plus (Jenoptik) and quantified using Multiscan 
18.03 Software (CSS, Warszawa). The number and percentage of degranulated 
Fig. 1. Mast cells in the rat stomach wall (cross-section). Toluidine blue staining.  
Mast cells red-purple (metachromatic staining) and the background blue (orthochromatic 
staining). Some cells degranulating (arrows). Magnification 400 ×
Ryc. 1. Komórki tuczne w ścianie żołądka szczura (przekrój poprzeczny). Barwienie błękitem 
toluidyny. Komórki tuczne różowo-fioletowe (barwienie metachromatyczne) a tło bladoniebieskie 
(barwienie ortochromatyczne). Nieliczne mastocyty degranulujące. Powiększenie 400 ×
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mast cells were counted semi-automatically in 5 serial slides of stomach (cor-
pus), duodenum and proximal colon made in each animal, in 10 consecutive 
visual fields under magnification 200 ×. The number of cells were then calcu-
lated for 10 area of view (AOV).
Data are expressed as mean and standard deviation (SD). Results were 
analysed by one-way analysis of variance (ANOVA), followed by LSD post-hoc 
test with Statistica 9.0 software package (StatSoft, Tulsa). Statistical signifi-
cance was set at p < 0.05.
RESULTS
Mast cells in the gastrointestinal wall were identified by light microscopy as 
purple-red stained cells with multiple granules (Fig. 1). Some of those cells 
were fully or partially degranulated.
Fig. 2. Cumulative mast cells count in the stomach, duodenum and proximal colon in control 
and salsolinol treated rats (n = 8 for each group). Cells were counted in 10 area of view with 
magnification 200 × in toluidine blue stained specimens in mucosa, muscularis externa and 
serosa. Data are presented as mean and standard deviation
Ryc. 2. Całkowita liczba komórek tucznych w żołądku, dwunastnicy i proksymalnym odcinku 
jelita grubego w grupie kontrolnej oraz u szczurów po podaniu salsolinolu  
(n = 8 dla każdej z grup). Mastocyty liczono w 10 polach widzenia pod powiększeniem 200 ×  
w preparatach barwionych błękitem toluidyny obejmujących całą grubość ściany.  
Wyniki przedstawiono jako średnie wraz z odchyleniem standardowym (SD)
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The number of mast cells was decreased in the salsolinol-treated group 
compared to the control — in stomach 98.7  ±  53.3 vs. 156.7  ±  45.8, — in duo-
denum 2.6  ±  2.1 vs. 7.83  ±  7.8 and — in colon 12.8  ±  14 vs.10.7  ±  17.1 (salsoli-
nol-treated group vs. control group) (Fig. 2).
The number of mast cells in the stomach muscularis externa was sig-
nificantly decreased in the salsolinol-treated group compared to the con-
trol — 48.5  ±  41.8 vs. 119.0  ±  35.2. In duodenum 2.4  ±  2.3 vs. 6.3  ±  7.2 
and in  colon — 0.75  ±  1.5 vs. 3.1  ±  1.9 (salsolinol-treated group vs. control 
group) the number of mast cells in muscularis externa remained unchanged 
(Fig. 3).
Fig. 3. Mast cells count in muscularis externa of the stomach, duodenum and proximal colon 
in control and salsolinol treated rats (n = 8 for each group). Cells were counted in 10 area 
of view with magnification 200 × in toluidine blue stained specimens. Data are presented as 
mean and standard deviation
Ryc. 3. Liczba komórek tucznych w błonie mięśniowej żołądka, dwunastnicy i proksymalnego 
odcinka jelita grubego w grupie kontrolnej oraz u szczurów po podaniu salsolinolu  
(n = 8 dla każdej z grup). Mastocyty liczono w 10 polach widzenia pod powiększeniem  
200 × w preparatach barwionych błękitem toluidyny. Wyniki przedstawiono jako średnie 
wraz z odchyleniem standardowym (SD)
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Surprisingly, the number of mast cells in the stomach mucosa was slightly 
but not significantly increased in salsolinol-treated group compared to control 
— 50.2  ±  16.1 vs. 37.7  ±  16.4 (Fig. 4). We did not find any changes in mast cells 
count in mucosa and muscularis externa in duodenum and proximal colon, 
because the small quantity of mast cells in these parts of gastrointestinal tract 
did not allowed to perform reliable statistical analysis.
Fig. 4. Mast cells count in mucosa of the stomach, duodenum and proximal colon in control 
and salsolinol treated rats (n = 8 for each group). Cells were counted in 10 area of view with 
magnification 200 × in toluidine blue stained specimens. Data are presented as mean and 
standard deviation
Ryc. 4. Liczba komórek tucznych w błonie śluzowej żołądka, dwunastnicy i proksymalnego 
odcinka jelita grubego w grupie kontrolnej oraz u szczurów po podaniu salsolinolu  
(n = 8 dla każdej z grup). Mastocyty liczono w 10 polach widzenia pod powiększeniem  
200 × w preparatach barwionych błękitem toluidyny. Wyniki przedstawiono jako średnie 
wraz z odchyleniem standardowym (SD)
The percentage of degranulated mast cells in the gastrointestinal wall was 
increased in the salsolinol-treated group compared to the control — in stom-
ach 77.96  ±  10.7 vs. 17.34  ±  8.9, — in duodenum 50.0  ±  50.0 vs. 9.0  ±  17.5 and 
— in colon 61.36  ±  45.4 vs. 14.44  ±  37.9 (salsolinol-treated group vs. control 
group) (Fig. 5).
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Fig. 5. Percentage of degranulated mast cells in the stomach, duodenum and proximal colon 
in control and salsolinol treated rats (n = 8 for each group). Cells were counted in 10 area of 
view with magnification 200 × in toluidine blue stained specimens in mucosa and muscularis 
externa. Data are presented as mean and standard deviation
Ryc. 5. Odsetek zdegranulowanych komórek tucznych w błonie śluzowej i błonie mięśniowej 
żołądka, dwunastnicy i proksymalnego odcinka jelita grubego u szczurów w grupie kontrolnej 
oraz po podaniu salsolinolu (n = 8 dla każdej z grup). Mastocyty liczono w 10 polach widzenia 
pod powiększeniem 200 × w preparatach barwionych błękitem toluidyny. Wyniki przedstawiono 
jako średnie wraz z odchyleniem standardowym (SD)
DISCUSSION
Mast cells develop from myeloid-cell progenitors under the influence of particu-
lar growth factors and are tissue cells typically located at important locations 
involved in host defence against the environment such as mucosal surfaces. 
The intestinal mucosa consists of around 2–3% of mast cells within the lamina 
propria in healthy individuals. In case of intestinal diseases, this amount can 
increase up to tenfold. For years, it has been generally accepted that mast 
cells are of relevance in gastrointestinal (GI) diseases such as food allergy, but 
recently, it became clear that mast cells participate in regulation of multiple 
tissue functions vital for gut homeostasis [10].
Animal models have proved valuable for studies of mast cells involvement 
in enteric immunoneural communication [3]. Infections with nematode para-
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sites (Nippostrongylus brasiliensis) stimulate proliferation of intestinal mast 
cells in animal models. A second exposure to the infectious agent triggers re-
lease of mast cells mediators, which become paracrine signals to the ENS [11]. 
Receptors for mast cells mediators are expressed on the terminals of vagal 
and spinal afferents [12]. The vagus is thus responsible, at the subconscious 
level, for carrying and modulating physiological information from the gastroin-
testinal tract [13]. Long-term vagal nerve stimulation increases the number of 
mast cells in the gastrointestinal wall, suggesting close anatomical associa-
tion between vagal fibres and enteric mast cells [14]. Stimulation of neurons 
in the brain stem by thyrotropin-releasing hormone evokes degranulation of 
mast cells in the rat small intestine adds another support for the brain-mast 
cell link [15]. The nerve — mast cell connection is significant because the gas-
trointestinal symptoms associated with mast cell degranulation are expected 
to be the same whether the mast cells are degranulated by antigen-antibody 
cross-linking in allergies or input from the ENS during stress conditions [3]. 
So, in fact, the communication is bi-directional, mast cells and nerves func-
tion as an integrated unit in the intestine. It appears that during inflammatory 
conditions, a positive feedback loop is established in which mast cells activate 
enteric nerves that further enhance mast cell activity, amplifying a secretory re-
sponse to eliminate the luminal antigen responsible for the initial response [1]. 
And, there is evidence that the central nervous system modulates mast cell 
function via a vagal efferent pathway exclusively [5, 15]. The intestinal mu-
cosa is uninterruptedly exposed to a load of antigens. The single-cell epithelial 
layer lining the gut lumen has the surface of around 300 m2 and is the most 
important barrier between the external and internal environment. The intesti-
nal barrier includes physical diffusion barriers, as well as enzymatic and im-
munological, all of which are under neurohormonal control. A breakdown of 
intestinal barrier function has been suggested as an etiologic factor in Crohn’s 
disease, and in pathogenesis of viral and bacterial gastroenteritis, ulcerative 
colitis, and multiple organ dysfunction syndrome in patients with sepsis and 
trauma. And mast cells undoubtedly play an essential role in stress-related gut 
mucosal dysfunction by increasing epithelial permeability, for both small and 
large molecules [16]. Experiments with rodents have demonstrated that mast 
cell proteases are directly responsible for the increase of epithelial paracellular 
permeability and for redistributed expression of tight junctions during parasitic 
infection and stress. The fact that mast cells are in close contact with epithelial 
cells and nerve endings underline the hypothesis that mast cells are involved in 
regulating mucosal permeability and therefore intestinal barrier function, and 
can contribute to an ongoing inflammatory process. The increased mucosal per-
meability may lead to an enhanced influx of potentially threatening microbes 
into the intestinal tissue [10]. Mast cells, itself, by virtue of their location are 
potential targets for environmental agents with immunotoxic effects and once 
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activated, secrete numerous vasoactive, neurosensitizing and proinflammatory 
molecules. Mast cell-derived mediators can increase gut-blood and blood-brain 
barrier (BBB) permeability. Selective release of Vascular Endothelial Growth 
Factor, especially its vasodilatory isoform, may lead to BBB disruption, per-
mitting brain inflammation. And selective release of IL-6 may also affect brain 
function and may influence hypothalamic-pituitary-adrenal axis [17].
Another neurotoxin, salsolinol, might represent a neuromodulator, which 
participates in the equilibrium of transmission of information at synapses com-
posed of presynaptic neurons synthesizing dopamine as their primary neuro-
transmitter [18]. Salsolinol and its metabolites can be detected in many areas 
of the brain, rich in dopamine, especially in the striatum [19]. It occurs that 
only (R) enantiomer of salsolinol is present in the brain, however, both (R) 
and (S) enantiomers are found in human plasma and urine [20]. The enanti-
omer selective occurrence of salsolinol suggests that it might be endogenously 
synthesized in nerve bodies or synaptic terminals of dopamine neurons. Any 
direct evidence is still missing. But, it is known that glial cells are able to 
take up a wide range of neurotransmitters [21]. Salsolinol could lead to neu-
rotoxicity by inhibition of mitochondrial complex II activity, increasing the 
formation of hydroxyl radicals or by initiation of apoptotic dopaminergic cell 
death [18].
Our results showed intestinal mucosal mast cells depletion in the gastroin-
testinal wall in the salsolinol-treated group in comparison with the control 
group. However at the same time the percentage of degranulated cells was 
raised in the salsolinol-treated group in comparison with the control group. We 
suggest then, it might be due to excessive mast cells degranulation caused by 
salsolinol. And once activated, mast cells might secrete a range of neurosen-
sitizing and proinflammatory molecules, increasing gut-blood and blood-brain 
barrier. 
Early involvement of the ENS is proposed in the pathogenesis of sporadic 
Parkinson’s disease. Neuroactive substances are usually taken up at synapses, 
where they are frequently controlled by receptor-mediated endocytosis and 
transported to the cell body via the axon. The absence of a myelin sheath around 
axons of the first neurons in the potential chain of vulnerable projection neu-
rons may facilitate entrance and damage by unknown pathogens. Most of the 
neurons located within the gastrointestinal wall, both intrinsic enteric neurons 
as well as extrinsic preganglionic parasympathetic and sympathetic fibres, lack 
such a protective barrier [7]. At the same time, the heterogeneity of pathological 
findings leading to a variety of alterations of GI motility underscore the need 
for appropriate animal models to investigate in depth the GI impairment in PD. 
At present, an ideal animal model is lacking [22]. Salsolinol and its active me-
tabolites may well participate in the equilibrium of information transmission at 
synapses where dopamine is the primary neurotransmitter [20] but it remains 
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unclear if the loss of dopaminergic neurons in the gut determines inhibition of 
contractility and constipation [22].
The mast cells in the gastrointestinal tract have been found in close spatial 
contact with the regulatory cells of gastrointestinal motility: interstitial cells 
of Cajal (ICC) and myenteric neurons, suggesting their functional interaction. 
Because of the regulatory role of mast cells even the slight damage or change 
in activity of these cells may cause considerable disorder of the gut motility in 
PD patients [11, 23].
Mast cells serve in both innate and adaptive immune responses, and con-
tribute to pathology of several disorders. However, many issues of mast cell 
biology still remains to be resolved, especially to what extent various envi-
ronmental factors may influence their population. Can mast cells generate 
functionally distinct subsets, or have sufficient plasticity to develop distinct 
features on the basis of their responsiveness to local or systemic environmental 
signals? And how the understanding of their biology can be exploited clinically, 
to promote health and decrease prevalence of disease?
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WPŁYW SALSOLINOLU NA KOMÓRKI TUCZNE PRZEWODU POKARMOWEGO SZCZURA
S t r e s z c z e n i e
Liczne wyniki badań wskazują, że komórki tuczne (mastocyty) odgrywają ważną rolę przekaźni-
kową oraz pozostają w ścisłym kontakcie z komórkami regulatorowymi przewodu pokarmowego 
— komórkami Cajala oraz neuronami splotów śródmięśniowych. Ze względu na regulacyjną funkcję 
komórek tucznych nawet niewielkie ich uszkodzenie może przełożyć się na znaczące zaburzenia 
funkcji przewodu pokarmowego.
Pochodne katecholowe z grupy izochinoliny należą do grupy związków endogennych obecnych 
w mózgu ssaków. Ich głównym przedstawicielem jest salsolinol — 1-metylo-6,7-dihydroksy-1,2,3,4- 
-tetrahydroizochinolina. Zaobserwowany u pacjentów z chorobą Parkinsona wzrost poziomu salso-
linolu może być jedną z przyczyn zaburzeń funkcji przewodu pokarmowego u tych pacjentów.
Celem przeprowadzonych badań była ocena wpływu egzogennego salsolinolu na komórki 
tuczne w przewodzie pokarmowym szczura. 
Szczury rasy Wistar (n = 8) otrzymywały dootrzewnowo salsolinol w dawce 50 mg/kg/dzień 
przez 3 tygodnie, a szczury grupy kontrolnej (n = 8) otrzymywały sól fizjologiczną. W ostatnim dniu 
eksperymentu szczury zgilotynowano i pobrano do badań fragmenty żołądka, dwunastnicy oraz 
jelita grubego. Ze skrawków parafinowych przygotowano preparaty, które wybarwiono błękitem 
 toluidyny. Określano liczbę mastocytów oraz procent zdegranulowanych komórek tucznych w ścia-
nie żołądka, dwunastnicy oraz części proksymalnej jelita grubego.
W grupie zwierząt otrzymujących salsolinol całkowita liczba komórek tucznych była mniejsza 
w porównaniu z grupą kontrolną we wszystkich odcinkach przewodu pokarmowego, a zwłasz-
cza w żołądku, natomiast odsetek komórek zdegranulowanych jest znamiennie wyższy w grupie 
szczurów poddanych działaniu salsolinolu.
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